<DOC>
	<DOCNO>NCT00988221</DOCNO>
	<brief_summary>This 3-part study evaluate efficacy safety tocilizumab patient active polyarticular-course juvenile idiopathic arthritis inadequate response , intolerant methotrexate . In Part I study , patient receive intravenous ( iv ) infusion tocilizumab ( 8 mg/kg patient ≥ 30kg , 8 mg/kg 10 mg/kg patient &lt; 30kg ) every 4 week 16 week . In Part II study , patient adequate response Part I randomize receive either tocilizumab dose Part I placebo every 4 week 24 week . In Part III study , patient receive tocilizumab dose Part I every 4 week another 64 week . Standard care therapy without non-steroidal anti-inflammatory drug ( NSAID ) , corticosteroid , methotrexate continue throughout study .</brief_summary>
	<brief_title>A Study Tocilizumab Patients With Active Polyarticular Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Children/juveniles , 217 year age . Polyarticularcourse juvenile idiopathic arthritis ( pcJIA ) ≥ 6 month duration . Active disease ( ≥ 5 active joint , ≥ 3 limitation motion ) . Inadequate response inability tolerate methotrexate . Methotrexate , oral corticosteroid , nonsteroidal antiinflammatory drug ( NSAID ) stable dose ( least 8 , 4 , 2 week , respectively ) prior baseline . Biologics discontinue , least 1 20 week prior baseline , depend biologic . Autoimmune , rheumatic disease overlap syndrome pcJIA . Wheelchair bound bedridden . Intraarticular , intramuscular , intravenous , longacting corticosteroid within 4 week prior baseline . Diseasemodifying antirheumatic drug ( DMARD ) ( methotrexate ) within 4 week prior baseline . Previous treatment tocilizumab .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>